Abbreviated fludarabine/mitoxantrone/rituximab chemotherapy followed by Zevalin [ibritumomab tiuxetan Y-90] for relapsed mantle cell lymphoma.
Phase of Trial: Phase II
Latest Information Update: 14 Oct 2017
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Fludarabine; Ibritumomab tiuxetan; Mitoxantrone; Rituximab
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 22 Apr 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 21 Feb 2013 Planned end date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 21 Feb 2012 Planned End Date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.